

CLAIMS

1. The therapeutical use of dihydrocyclosporin D for the treatment of multiple sclerosis.
2. The use according to claim 1, characterized by the administration of dihydrocyclosporin D in a daily dosage of between ca. 75 and 3500 mg.
3. A medicament for the treatment of multiple sclerosis, characterized in that it contains dihydrocyclosporin D as the active ingredient.
4. A pharmaceutical composition for the treatment of multiple sclerosis, characterized in that it contains dihydrocyclosporin D in admixture with a pharmaceutically acceptable diluent or carrier.
5. A pharmaceutical composition according to claim 4, characterized in that it is present in the form of unit doses for oral administration.
6. A pharmaceutical composition according to claim 5, characterized in that the unit doses contain between ca. 15 and 1750 mg of dihydrocyclosporin D.
7. Products and processes substantially as described above, with reference to the examples mentioned.

26th January 1983

SANDOZ S.A.